Skip to main content
. 2021 May 12;156(4):679–690. doi: 10.1093/ajcp/aqab010

Figure 3.

Figure 3

Clinical impact of Revised International Prognostic Scoring System (IRSS-R) and presence of transcription factor (TF) comutations on overall survival (OS) and progression-free survival (PFS) in myelodysplastic syndrome (MDS) harboring SF3B1 mutations (MDS-SF3B1). A, OS in patients with IPSS-R scores greater than 3 vs 3 or lower (P = .002). B, OS in patients with TF comutations vs without TF mutations (P = .0003). C, PFS in patients with IPSS-R scores greater than 3 vs 3 or lower (P = .006). D, PFS in patients with TF comutations vs without TF mutations (P = .0001).